Skip to content
The Kids Research Institute Australia logo

Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment

We aimed to assess safety, tolerability, and Plasmodium vivax relapse rates of ultra-short course (3.5 days) high-dose (1 mg/kg twice daily) primaquine (PQ) for uncomplicated malaria because of any Plasmodium species in children randomized to early- or delayed treatment.

Citation:
Woon SA, Moore BR, Laman M, Tesine P, ……. Salman S, Robinson LJ, Davis TME, Manning L. Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment. Int J Infect Dis. 2023;130:189-95.

Keywords:
Malaria; Pediatric; Plasmodium falciparum; Plasmodium vivax; Primaquine; Radical cure; Universal cure

Abstract:
We aimed to assess safety, tolerability, and Plasmodium vivax relapse rates of ultra-short course (3.5 days) high-dose (1 mg/kg twice daily) primaquine (PQ) for uncomplicated malaria because of any Plasmodium species in children randomized to early- or delayed treatment.